Recently, KingMed Diagnostics issued a profit forecast indicating that its net profit attributable to shareholders of the parent company is expected to turn negative in 2025. This projection stems from several key factors: first, the optimization of China’s COVID-19 control policies has led to a sharp decline in pandemic-related testing demand, significantly reducing revenue from its core business; second, intensifying competition in the third-party medical testing industry has driven down service prices, squeezing profit margins; additionally, ongoing investments in R&D, laboratory infrastructure, and talent acquisition have increased operating costs in the short term. Despite current profitability challenges, KingMed reaffirms its long-term strategic commitment, focusing on high-quality diagnostic services, expanding specialized testing offerings, and broadening its regional footprint to enhance competitiveness. Market analysts note that the anticipated short-term loss does not signal fundamental deterioration but rather reflects normal adjustments during an industry cycle and strategic transition phase. Investors should closely monitor the company’s progress in business restructuring and the pace of its return to profitability.
近日，金域医学发布业绩预告，预计2025年归属于母公司股东的净利润将为负值。这一预测主要受到多重因素影响：首先，随着新冠疫情防控政策的优化，与疫情相关的检测需求大幅下降，导致公司核心业务收入显著减少；其次，行业竞争加剧，第三方医学检验服务价格持续承压，压缩了整体利润空间；此外，公司在技术研发、实验室建设及人才引进等方面的持续投入，短期内也增加了运营成本。尽管当前面临盈利压力，金域医学仍强调其长期发展战略不变，将继续聚焦高质量医学检验服务，拓展特检项目和区域布局，以提升核心竞争力。市场分析人士指出，短期亏损并不意味着公司基本面恶化，而是行业周期性调整与战略转型期的正常表现。投资者需关注其后续业务结构调整成效及盈利能力恢复节奏。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/13714.html